Clinical relevance of BRCA1 promoter methylation testing in ovarian cancer patients.
Homologous-recombination deficiency (HRD) is closely related to PARPi benefit in ovarian cancer (OC). The capacity of BRCA1 promoter methylation to predict prognosis and HRD status remains unclear.  We aimed to correlate BRCA1 promoter methylation levels in patients with high-grade OC to HRD status and clinical behavior to assess its clinical relevance. Overall design: The detection of BRCA1 promoter methylation and quantification of methylation levels were performed by quantitative ddPCR methodology. bisulfite-conversion + ddPCR